EE653 Efficacy of Targeted Drugs for the Treatment of Adults With Moderate-to-Severe Plaque Psoriasis in the Russian Federation: Number Needed to Treat and Costs Per Responder

Abstract

To reassess the number of adults with moderate-to-severe plaque psoriasis needed to treat (NNT) to achieve one Psoriasis Area and Severity Index (PASI) 75/90 response and costs per responder (CpR) after 12 weeks for adalimumab (ADA), infliximab (INF), etanercept (ETN), ixekizumab (IXE), netakimab (NTK), secukinumab (SEC), ustekinumab (UST), tofacitinib (TOFA), and apremilast (APR) and after 16 weeks for certolizumab pegol (CZP), risankizumab (RIS) and guselkumab (GUS) and 1 year of therapy for each drug analyzed.